Alexander Duncan is a leading antibody research scientist and business leader and member of the executive management team.

At Astra Zeneca he was a member of AZ Discovery senior management team and SVP Biopharmaceuticals. He led the Cambridge UK Discovery site, previously Cambridge Antibody Technology (CAT), through its integration with Medimmune. Prior to its acquisition by Astra Zeneca, Alex was SVP Drug Discovery at CAT, where he built a recognized world class antibody discovery capability. In addition to playing a major role in the creation of the CAT-AZ alliance, he led CAT discovery collaborations with Wyeth, Merck, Human Genome Sciences, Elan, Pfizer, Immunex and others.

Alex gained his PhD in Dr. Sir Greg Winter's laboratory at the MRC Laboratory of Molecular Biology, University of Cambridge and held post-doctoral positions at the University of California San Diego.